Brought to you by 
Cortexyme completes $15.9mm Pfizer-led Series A round
21 Jan 2016
Executive Summary
Cortexyme Inc. (therapeutics and diagnostics for neurodegenerative diseases) raised $15.9mm in a Series A round from 13 investors led by Pfizer Inc.; other participants included new backer Takeda Pharmaceutical and seed investor Dolby Family Ventures.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cortexyme completes $15.9mm Pfizer-led Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice